Do you want to read an article? Please log in or register.
Managing Side Effects in Breast Cancer Treatment
Breast Cancer
SPECIAL REPORT
Related content
SPECIAL REPORT
Breast Cancer
Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study
Breast Cancer
Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer
Ann Oncol
Burstein HJ, Curigliano G, Gnant M, Loibl S, Regan MM, Loi S, Denkert C, Poortmans P, Cameron D, Thurlimann B, Weber WP, Panelists of the St. Gallen International Breast Cancer Consensus 2025
doi: 10.1016/j.annonc.2025.09.007
COMMENTED
Further Publications
Effect of low-dose tamoxifen on benign gynecological and breast conditions in a phase III trial in non-invasive breast cancer
★ 1
Recommended and commented by
Dr Andreas Müller, Faculty Member
★ 2
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
J Natl Cancer Inst
Carbone A, Oliva M, Puntoni M, Guerrieri-Gonzaga A, Briata IM, Lazzeroni M, Serrano D, Giordano L, Digennaro M, Cortesi L, Millo F, Cagossi K, Aprile G, Serra P, Gallerani E, Bonanni B, DeCensi A
doi: 10.1093/jnci/djaf250
Breast Cancer
18F-Fluorodeoxyglucose Positron Emission Tomography for Estimating Outcomes After Initial Treatment for Metastatic Breast Cancer: A Nonrandomized Clinical Cohort Trial
JAMA Oncol
van Geel JJL, Eisses B, Elias SG, Brouwers AH, Bensch F, Gerritse SL, Angus L, Glaudemans AWJM, Kuip EJM, Jager A, Oprea-Lager DE, Vugts DJ, Emmering J, Arens AIJ, Oyen WJG, van der Vegt B, Lub-de Hooge MN, Menke-van der Houven van Oord CW, de Vries EGE, Schröder CP, IMPACT-Metastatic Breast Cancer Consortium
doi: 10.1001/jamaoncol.2026.0767
COMMENTED
Breast Cancer
Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer
★ 3
Recommended and commented by
Dr Andreas Müller, Faculty Member
J Natl Cancer Inst
Tarantino P, Lee D, Foldi J, Soulos PR, Gross CP, O'Meara T, Grinda T, Morganti S, Waks AG, Winer EP, Lin NU, Krop IE, Tolaney SM, Sammons S, Lustberg M
doi: 10.1093/jnci/djaf220
Further Publications
Cost-Effectiveness of Adjuvant Immunotherapy in Cancer Treatments: A Systematic Review
JAMA Oncol
Mahumud RA, Chen Y, Shahjalal M, Dahal PK, Alam K
doi: 10.1001/jamaoncol.2025.6080
Breast Cancer
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial
Eur J Cancer
Wortelboer N, Kent S, Konings IR, van Ommen-Nijhof A, van der Noort V, van den Pol E, Guerrero Páez C, van Bekkum ML, van den Berkmortel FWPJ, Droogendijk HJ, Houtsma D, Oosterkamp HM, van der Padt-Pruijsten A, Siemerink EJM, Tol J, van Zweeden AA, van Leeuwen-Stok AE, Sonke GS, Jager A, Blommestein HM
doi: 10.1016/j.ejca.2025.116051
Breast Cancer
Long and short-term efficacy and safety comparison of nab-paclitaxel versus paclitaxel combined with trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer: A systematic review and meta-analysis
Cancer Treat Rev
Yuan Y, Long X, Wei M, Chen L, Zhang J, Liu X
doi: 10.1016/j.ctrv.2025.102975
Breast Cancer
Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR-positive/HER2-negative metastatic breast cancer: Real-world data from the OPAL registry
Int J Cancer
Marschner P, Ringwald K, Thill M, Zahn MO, Welt A, Nusch A, Kaltenecker G, Rodemer Y, Hagen V, Schock C, Kruggel L, Kaiser-Osterhues A, Klein D, Haug N, Stickeler E, Harbeck N, Wöckel A, Marschner N, Decker T, OPAL Registry Group
doi: 10.1002/ijc.70433